EGFR and metastatic malignant neoplasm in the lymph nodes: There was no statistically significant difference in immune or stromal scores between patients who were < 65 and ≥65 years of age; between female and male patients; between patients with and without lymph node metastasis; between patients with and without distant metastasis; or between patients with and without epidermal growth factor receptor (EGFR)/KRAS proto-oncogene, GTPase (KRAS) mutation (data not shown).